Construction method and application of goat mammary epithelial cells overexpressed by Timd4 gene
The Timd4 gene overexpression model was constructed in goat breast epithelial cells through CRISPR/Cas9 gene editing technology, which solved the shortcomings of Timd4 gene function, achieved Timd4 gene overexpression in breast epithelial cells, and significantly inhibited LPS-induced inflammation Response provides theoretical support for gene therapy for mastitis.
Patent Information
- Application Number
- CN202410828101.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-25
- Publication Date
- 2024-12-06
AI Technical Summary
In the prior art, the function of Timd4 gene in non-phagocytic cells is less studied, especially in breast epithelial cells, and there is a lack of effective methods to construct a cell model of Timd4 gene overexpression to study its Function in inflammatory response.
Using CRISPR/Cas9 gene editing technology, the promoter encoding the Timd4 gene was replaced with a promoter that strongly expressed the b-actin gene. The goat breast epithelial cells stably overexpressing the Timd4 gene were constructed through gene editing technology, and LPS was used to induce it. inflammatory response model evaluates its function.
The successful construction of goat breast epithelial cells with Timd4 gene overexpression significantly reduced the expression of inflammatory factors induced by LPS, providing a theoretical basis for gene therapy for mastitis.
Smart Images

Figure CN119082201A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of genetic engineering, and in particular to a construction method and application of goat mammary epithelial cells with overexpression of Timd4 gene. Background Art
[0002] The T cell immunoglobulin and mucin domain (TIM) family is a recently discovered group of transmembrane molecules that share an immunoglobulin variable (IgV) domain with six cysteines, a mucin-like domain, a transmembrane domain, and a cytoplasmic domain. There are eight members in mice (TIM1-TIM8) and three members in humans (TIM1, TIM3, and TIM4). TIMs are involved in regulating innate and adaptive immune responses, such as allergy, asthma, autoimmunity, and transplant tolerance.
[0003] TIM-4 (also TIMD4) is a member of the TIM family. It mainly acts as a phosphatidylserine receptor to enhance the phagocytosis of apoptotic cells. Immunostaining shows that phagocytic active cells in the spleen, lymph nodes, and other tissues express TIMD4. A large number of studies have shown that TIMD4 is a new molecule that is closely related to chronic inflammation, such as gastroenteritis, atopic dermatitis, and asthma. In addition, overexpression of TIMD4 in fibroblasts confers "gain of function" and enhances the uptake of apoptotic cells. At present, research on the TIMD4 gene is mostly focused on phagocytic cells, and there is little research on its function in non-phagocytic cells. Therefore, it is of great significance to study the role of TIMD4 in mammary epithelial cell infection. Summary of the invention
[0004] In view of the deficiencies in the prior art, the present invention aims to provide a method for constructing goat mammary epithelial cells overexpressing the Timd4 gene and its application. Using goat primary mammary epithelial cells as materials, the CRISPR / Cas9 gene editing technology is used to replace the promoter encoding the Timd4 gene with an endogenous strong promoter to achieve high expression. After obtaining the positive clone cell line, the recombination efficiency is evaluated by quantitative and protein immunoblotting, and the function of the Timd4 gene in the mastitis model is evaluated by LPS-induced inflammatory response, so as to obtain mammary epithelial cells that stably overexpress the goat Timd4 gene and are anti-inflammatory.
[0005] In order to solve the above technical problems, the technical solution provided by the present invention is:
[0006] Method for constructing goat mammary epithelial cells overexpressing Timd4 gene,
[0007] Using gene editing technology, the promoter encoding the Timd4 gene was replaced with the promoter of the endogenous b-actin gene, which strongly expressed the Timd4 gene, and primary mammary epithelial cells that stably overexpressed the goat Timd4 gene were obtained.
[0008] The specific steps include:
[0009] S1. Amplification of the repair fragment b-actin promoter: Using goat genomic DNA as a template, the b-actin promoter was amplified by PCR and purified; the nucleotide sequence of the b-actin promoter is shown in SEQ ID No.1;
[0010] S2. Amplification of the left homology arm and the right homology arm of the Timd4 gene: Using the genomic DNA of goat Timd4 as a template, 1 kb before and after the 5'UTR of the Timd4 gene were used as the left and right homology arms, and PCR amplification and purification were performed; the nucleotide sequence of the left homology arm of the Timd4 gene is shown in SEQ ID No.2; the nucleotide sequence of the right homology arm of the Timd4 gene is shown in SEQ ID No.3;
[0011] S3. Preparation of Donor linear backbone: pZ-Tomato plasmid was double-digested with Sal I endonuclease and Hind III endonuclease, purified, and Donor linear backbone was obtained;
[0012] S4. Construction of pZ-Tomato-Timd4 plasmid: digest the b-actin promoter obtained in S1 and the left homology arm and right homology arm fragments of the Timd4 gene obtained in S2, and connect them to obtain homology arm fragments: left homology arm-promoter-right homology arm; connect the homology arm fragments with the Donor linear skeleton obtained in S3 to construct pZ-Tomato-Timd4 plasmid;
[0013] S5. Construction of pX459-Timd4 plasmid: Determine the PAM site of the Timd4 gene promoter and construct a double-stranded gRNA fragment; after the pX459 vector is digested with Bbs I, the double-stranded gRNA fragment is connected to the pX459 plasmid vector to obtain the pX459-Timd4 plasmid;
[0014] S6. The pX459-Timd4 plasmid obtained in S5 and the pZ-Tomato-Timd4 plasmid obtained in S4 were electroporated into goat mammary epithelial cells at a mass ratio of 1:1, and resistance screening was performed to obtain mammary epithelial cells that stably overexpressed the goat Timd4 gene.
[0015] Preferably,
[0016] The sequence of the gRNA is shown in SEQ ID No.10 and SEQ ID No.11.
[0017] Preferably,
[0018] The sequences of the primers used for amplifying the repair fragment b-actin promoter in S1 are shown in SEQ ID No.4 and SEQ ID No.5.
[0019] Preferably,
[0020] The sequences of the primers used to amplify the left homologous arm of the Timd4 gene in S2 are shown in SEQ ID No.6 and SEQ ID No.7; the sequences of the primers used to amplify the right homologous arm of the Timd4 gene are shown in SEQ ID No.8 and SEQ ID No.9.
[0021] Preferably,
[0022] The verification primer sequences of the pX459-Timd4 plasmid in S5 are shown in SEQ ID No.11 and SEQ ID No.12.
[0023] Preferably,
[0024] The mass ratio of the left and right homology arms and the promoter in S4 is 1:1:2; the homology arm fragments and the Donor linear backbone are connected by Gibson, and the mass ratio of the homology arm fragments and the Donor linear backbone is 2:1.
[0025] Goat mammary epithelial cells overexpressing the Timd4 gene were constructed according to the above method.
[0026] The application of Timd4 gene overexpressing goat mammary epithelial cells constructed according to the above method in constructing an inflammatory response animal model.
[0027] Preferably,
[0028] The steps to construct an animal model of inflammatory response are:
[0029] After wild-type goat mammary epithelial cells and gene-overexpressing mammary epithelial cells were revived, when the cell confluence reached 70% to 80%, 10 μg / mL LPS was added for treatment for 12 hours, total cell mRNA was extracted, and the expression levels of inflammatory factor genes were detected by real-time fluorescence quantitative PCR.
[0030] Preferably,
[0031] The sequences of the primers for PCR detection of inflammatory factors are shown in SEQ ID No. 13 to SEQ ID No. 22. The beneficial effects of the present invention are:
[0032] The present invention utilizes CRISPR / Cas9 gene editing technology, uses goat primary mammary epithelial cells as materials, replaces the promoter encoding the Timd4 gene with the promoter of the endogenous b-actin gene that strongly expresses, and overexpresses the Timd4 gene to obtain primary mammary epithelial cells that stably overexpress the goat Timd4 gene. The present method provides a method for constructing Timd4 gene overexpression, and the goat mammary epithelial cells overexpressing the Timd4 gene obtained by the method can effectively protect the mammary epithelial cells from LPS-induced inflammatory response, providing theoretical support for the field of mastitis gene therapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the embodiments of the present invention, they are used to explain the present invention and do not constitute a limitation of the present invention. In the accompanying drawings:
[0034] Figure 1 A strategy for site-directed overexpression of the Timd4 gene based on the CRISPR / Cas9 system
[0035] Figure 2 Maps of pX459 plasmid backbone and pZ-Tomato plasmid backbone targeting Timd4 gene
[0036] Figure 3 The Timd4 gene homology arm fragment and the b-actin promoter amplified fragment map
[0037] Figure 4 PCR verification diagram of pZ-Tomato-Timd4 plasmid restriction enzyme cutting
[0038] Figure 5 Figure 2 shows the stably transfected goat mammary epithelial cells after overexpression of Timd4 gene
[0039] Figure 6 The expression results of Timd4 mRNA and protein levels in goat mammary epithelial cells with overexpression of Timd4 gene
[0040] Figure 7 The expression results of inflammatory gene mRNA in goat mammary epithelial cells with overexpression of Timd4 gene after infection DETAILED DESCRIPTION
[0041] The preferred embodiments of the present invention are described below in conjunction with the accompanying drawings. It should be understood that the following embodiments are provided only for the purpose of illustration and are not intended to limit the scope of the present invention. Those skilled in the art may make various modifications and substitutions to the present invention without departing from the purpose and spirit of the present invention.
[0042] definition
[0043] As used herein, the terms "polynucleotide", "nucleotide", "nucleotide sequence", "nucleic acid" and "oligonucleotide" are used interchangeably and refer to a polymeric form of nucleotides (deoxyribonucleotides or ribonucleotides) of any length or their analogs. Examples of polynucleotides include, but are not limited to, coding or non-coding regions of genes or gene fragments, exons, introns, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA), short hairpin RNA (shRNA), micro-molecule RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, DNA isolated from any sequence, RNA isolated from any sequence, nucleic acid probes and primers. One or more nucleotides in a polynucleotide may be further modified. The sequence of nucleotides may be interrupted by non-nucleotide components. Polynucleotides may also be modified after polymerization, for example by coupling with a labeling agent. "CRISPR / Cas9" is an adaptive immune defense formed by bacteria and archaea during long-term evolution, which can be used to fight invading viruses and foreign DNA. CRISPR / Cas9 gene editing technology is a technology for specific DNA modification of targeted genes. Gene editing technology based on CRISPR / Cas9 has shown great application prospects in a series of gene therapy application fields, such as blood diseases, tumors and other genetic diseases. This technical achievement has been applied to the precise modification of the genomes of human cells, zebrafish, mice and bacteria. The terms "gRNA", "guide RNA" and "CRISPR guide sequence" used in this article can be used interchangeably throughout and refer to RNA containing specific sequences that determine the Cas protein in the CRISPR / Cas system. The gRNA hybridizes with the target nucleic acid sequence in the host cell genome (partially or completely complementary). The length of the gRNA or part thereof hybridized with the target nucleic acid sequence may be between 15-25 nucleotides, 18-22 nucleotides or 19-21 nucleotides. In some embodiments, the length of the gRNA sequence hybridized with the target nucleic acid sequence may be 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides. In some embodiments, the length of the gRNA sequence hybridized to the target nucleic acid is between 10-30 or 15-25 nucleotides. "sgRNA" refers to a single-molecule guide RNA or a single-stranded guide RNA in the artificial CRISPR / Cas9 system, which refers to the RNA that guides the Cas protein to specifically bind to the target DNA sequence, and is an important component of the CRISPR gene knockout knock-in system. The sgRNA comprises a guide sequence that targets the target sequence. In a preferred embodiment, the sgRNA further comprises a tracr sequence and a tracr partner sequence.
[0044] "Guide sequence" refers to a sequence of about 17-20bp that specifies a targeting site, and can be used interchangeably with "guide sequence" or "spacer". In the context of forming a CRISPR complex, the "target sequence" is a sequence that the guide sequence is designed to have complementarity with, wherein hybridization between the target sequence and the guide sequence promotes the formation of the CRISPR complex, and hybridization requires that the "target sequence" and the "guide sequence" or "guide sequence" have sufficient complementarity to cause hybridization and promote the formation of the CRISPR complex, and complete complementarity is not required. "Complementary" means that the "guide sequence" or "guide sequence" and the target nucleotide sequence (in the case of the present invention, the target nucleotide sequence in the third exon region of the FTO gene of the cell line) can hybridize through the nucleotide pairing principle discovered by Watson and Crick. Those skilled in the art will understand that as long as there is sufficient complementarity, the "guide sequence" can hybridize with the target nucleotide sequence without the need for 100% complete complementarity between them. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence can be about or greater than about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more when optimally aligned using an appropriate alignment algorithm. Optimal alignment can be determined using any suitable algorithm for aligning sequences, including the Smith-Waterman algorithm, the Needleman-Wimsch algorithm, an algorithm based on the Burrows-Wheeler Transform, and the like.
[0045] Typically, in the context of an endogenous CRISPR system, formation of a CRISPR complex (including hybridization of a guide sequence to a target sequence and complexing with one or more Cas proteins) results in cleavage of one or both strands in or near the target sequence (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or more base pairs from the target sequence). The tracr sequence may comprise all or a portion of a wild-type tracr sequence, e.g., about or greater than about 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 70, 75, 80, 85 or more nucleotides of a wild-type tracr sequence) or consist of the above tracr sequence can also form part of a CRISPR complex, e.g., by hybridization along at least a portion of the tracr sequence to all or a portion of a tracr partner sequence operably linked to a guide sequence.
[0046] In some embodiments, the tracr sequence has sufficient complementarity with the tracr partner sequence to hybridize and participate in the formation of the CRISPR complex. Similar to the hybridization of the "target sequence" and the "guide sequence" or "guide sequence", complete complementarity is not required, as long as it is sufficient to perform its function. In some embodiments, the tracr sequence has at least 50%, 60%, 70%, 80%, 90%, 95% or 99% complementarity with the length of the tracr partner sequence under optimal alignment.
[0047] "Gene overexpression" or "overexpression" refers to editing a gene in a mammary epithelial cell (e.g., inserting, replacing, and / or deleting the gene) so that the gene acquires function (e.g., overexpressing a functional protein). Genes in the cell genome can be edited using various known molecular biology techniques (e.g., using zinc finger nuclease-based gene editing technology, TALEN gene editing technology, and CRISPR / Cas (e.g., CRISPR / Cas9) gene editing technology).
[0048] "Vector" refers to a nucleic acid carrier into which a polynucleotide can be inserted. When a vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries are expressed in the host cell. Vectors include, but are not limited to: plasmids; phagemids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC); bacteriophages such as λ phage or M13 phage and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses (such as SV40). A vector can contain a variety of elements that control expression, including but not limited to promoter sequences, transcription start sequences, enhancer sequences, selection elements and reporter genes. In addition, the vector may also contain a replication start site.
[0049] The present invention provides a method for constructing goat mammary epithelial cells that overexpress the Timd4 gene based on the CRISPR / Cas9 system and an application thereof, comprising: utilizing gene editing technology, taking goat primary mammary epithelial cells as materials, and overexpressing the Timd4 gene by a promoter replacement method to obtain mammary epithelial cells that stably overexpress the goat Timd4 gene and are anti-inflammatory.
[0050] After knowing the efficient gene editing region (the promoter region of the Timd4 gene in the present invention), those skilled in the art can use any gene editing method, such as zinc finger nuclease-based gene editing technology, TALEN gene editing technology and CRISPR / Cas (such as CRISPR / Cas9) gene editing technology and other gene editing methods discovered in the future, to edit the known efficient gene editing region, optimize the gene editing conditions, and achieve the purpose of efficient editing. Therefore, the present invention covers the technical solution of knocking out the promoter region target sequence of the Timd4 gene identified by the present invention by any available gene editing method. In a specific embodiment, the present invention overexpresses the Timd4 gene of mammary epithelial cells through CRISPR / Cas9 technology, wherein the gRNA used to target the Timd4 gene of mammary epithelial cells in the CRISPR / Cas9 technology comprises a nucleotide sequence complementary to the promoter region of the Timd4 gene of mammary epithelial cells.
[0051] Figure 1 This is a Timd4 gene site-directed overexpression strategy based on the CRISPR / Cas9 system. Figure 2 Maps of pX459-Timd4 plasmid and pZ-Tomato-Timd4 plasmid targeting Timd4 gene.
[0052] Example 1
[0053] Instruments used in the present invention:
[0054] 96-well plate (centrifuge Beijing Dinghaoyuan Technology Co., Ltd.), electronic balance (METTLER TOLEDO, Switzerland), inverted fluorescence microscope (AMG), constant temperature water bath (Shanghai Zhicheng Analytical Instrument Manufacturing Co., Ltd.), agarose horizontal electrophoresis instrument (Beijing Liuyi Biotechnology Co., Ltd.), protein transfer instrument (Bio-Rad, USA), real-time fluorescence quantitative PCR instrument (ABI, USA), CO 2 Constant temperature cell culture incubator (Thermo Fisher), cell electroporation instrument (NEPAGENE).
[0055] Reagents used in the present invention:
[0056] Blood / cell / tissue genomic DNA extraction kit (TIANGEN, DP304-02), endotoxin-free plasmid extraction kit (Magen, P1156-02), KOD FX NEO high-efficiency PCR enzyme (TOYOBO, KFX-201), DH5α (Kangwei Century, CW0808B), ampicillin storage solution (Coolaber, SL3810), SalI restriction endonuclease (NEB, R3138V), BbsI restriction endonuclease (NEB, R3539S), HindIII restriction endonuclease (R0104S, NEB), T4 DNA ligase (M0201S, NEB), nucleic acid dye (CooLaber, SL2140), 1kb DNA ladder (Zhongke Ruitai, RTM417), CloneExpressIIOne Step Clonging Kit (Vazyme, C112), DMEM-F12 medium (Gibco, A4192001), FBS (Gibco, 16140071), DMSO (Sigma, D2650), penicillin-streptomycin double antibody (Invitrogen, 15140122), recombinant human insulin (Solarbio, I8830-20), recombinant human EGF (Sangong, c610033-0100), dexamethasone (Sangong, A601187-0005), 0.25% Trypsin-EDTA (1×) (Gibco, 25200-072), Trizol (Mei5, C0121), StarScript III one-tube de-genomic reverse transcription master mix (GenStar, A230-10), Hieff qPCR SYBRGreen Master Mix (High Rox Plus) (YEASEN, 11203ES08), Prestained Protein Ladder (Life, 26619), recombinant Anti-TIM4 antibody (Cell Signaling Technology, 75484), RIPA cell lysis buffer (strong) (Beyotime, P0013B), RNasin Inhibitor (Promega, N2112S), SDS-PAGE gel preparation kit (Beyotime, P0012A), TEMED (Beyotime, ST728), 30% Arc-Bis (Beyotime, ST003), 1.0M Tris-HCl (pH 6.8) (Beyotime, ST768), PhosSTOP (Roche, 04906845001), 1.5M Tris-HCl (pH8.8) (Beyotime, ST789), Western primary antibody diluent (Beyotime, P0256), Western secondary antibody diluent (Beyotime, P0258), 0.25% Trypsin-EDTA (Gibco, 25200056), PVDF membrane (Beyotime, FFP24), skim milk powder (Yili Group, 422535), PMSF (100mM) (Beyotime, ST506). .
[0057] This embodiment provides a method and application for constructing goat mammary epithelial cells for site-directed overexpression of the Timd4 gene based on the CRISPR / Cas9 system, comprising the following steps:
[0058] Step 1: Amplification of the b-actin promoter (repair fragment)
[0059] Using goat genomic DNA as a template, the b-actin promoter (i.e., the repair fragment) was amplified by PCR and purified. The nucleotide sequence is shown in SEQ ID No. 1 in Table 1. The PCR reaction system and reaction conditions are shown in Table 2. RF F1 / RF R1 are b-actin primers containing homology arms, and the nucleotide sequences are shown in SEQ ID No. 4 and SEQ ID No. 5 in Table 3. The PCR product was electrophoresed with 1% agarose gel (100V, 15min), stained in EB for 30min, and the target band was verified under ultraviolet light. The size of the target band was 2kb. The results are shown in Figure 3 The obtained PCR product was stored in a -20°C refrigerator for future use.
[0060] Step 2: Amplification of the homology arms of the Timd4 gene
[0061] Using goat genomic DNA as a template, 1 kb before and after the 5'UTR of the Timd4 gene was used as the left and right homology arms. The nucleotide sequences were shown in SEQ ID No. 2 and SEQ ID No. 3 in Table 1. PCR amplification and purification were performed. The reaction system and reaction conditions are shown in Table 2. RF F2 / RF R2 and RF F3 / RF R3 are the left and right homology arm primers containing b-actin. The nucleotide sequences are shown in SEQ ID No. 6, SEQ ID No. 7 (left homology arm); SEQ ID No. 8, SEQ ID No. 9 (right homology arm) in Table 3. The PCR product was electrophoresed (100 V, 15 min) using 1% agarose gel and stained in EB for 30 min. The target band was verified under ultraviolet light. The size of the target band was 1 kb. The results are as follows. Figure 3 The obtained PCR product was stored in a -20°C refrigerator for future use.
[0062] Table 1b-actin promoter (repair fragment) and Timd4 gene left and right homologous arm sequence list
[0063]
[0064]
[0065]
[0066]
[0067] Table 2 PCR amplification reaction system and reaction conditions Reaction system
[0068]
[0069] Reaction conditions
[0070]
[0071] Table 3 b-actin primers containing homology arms and left and right homology arm primers
[0072]
[0073]
[0074] Step 3: Preparation of Donor Linear Skeleton
[0075] The Donor linear backbone enzyme digestion system and reaction conditions are shown in Table 4. Double digestion was performed with Hind III endonuclease and Sal I endonuclease. The amount of Sal I and Hind III added to the reaction system was determined according to the template amount of the pZ-Tomato plasmid. The Donor linear backbone was obtained after purification.
[0076] Table 4 Donor linear backbone template enzyme digestion system
[0077]
[0078] Step 4: Construction of pZ-Tomato-Timd4 plasmid
[0079] The promoter sequence obtained in step 1 and step 2 and the left and right homology arm sequences were connected by left homology arm-promoter-right homology arm to obtain homology arm fragments, and connected to the Donor linear backbone to construct the pZ-Tomato-Timd4 plasmid;
[0080] (1) The amplified left and right homology arms and the promoter were added to the connection system at a mass ratio of 1:1:2 to obtain homology arm fragments. The homology arm fragments and the Donor linear backbone were added to the connection system at a mass ratio of 2:1. The promoter, homology arm fragments and the Donor linear backbone were connected by Gibson to obtain the pZ-Tomato-Timd4 plasmid. The connection system is shown in Table 5 and Table 6. 10 μL of each reaction system was subjected to PCR reaction at 37°C for 30 min to obtain a reaction solution.
[0081] (2) Take 10 μL of the reaction solution for E. coli transformation.
[0082] (3) After transformation, the cells are first spread on LB-Amp plates. After the strain grows, it is streaked on the LB-Amp plate and cultured at 37°C for 12 hours. A small amount of cells is transferred to a test tube containing 5 mL of LB+Amp liquid culture medium and cultured for 12 to 16 hours (120 rpm, 37°C).
[0083] (4) Collect the bacteria and use a plasmid DNA large-scale extraction kit to extract the pZ-Tomato-Timd4 plasmid from Escherichia coli.
[0084] (5) After enzyme digestion, the pZ-Tomato-Timd4 plasmid and the digestion product were subjected to electrophoresis (100 V, 15 min) using 0.7% agarose gel, stained in EB for 30 min, and the target band was verified under ultraviolet light. The results are as follows Figure 4 As shown, the left figure is a schematic diagram of the construction of the pZ-Tomato-Timd4 plasmid, the fragment size is 11,577bp, and after single digestion with EcoR I endonuclease, 10260bp, 9305bp, 8884bp, 6282bp, 5295bp, 2693bp, 2272bp and 1317bp bands are expected to be produced. The right figure is an agarose gel image of the PZ-Tomato-Timd4 plasmid extracted from a single clone after digestion. After single digestion with 1#, 6# and 9#, bands less than 1.5kbp, 3kbp and 6kbp appear, which are preliminarily determined to be the expected plasmid, and the subsequent DNA purification step can be carried out. The DNA ladder used in the agarose gel is 1kb plus Marker. The obtained pZ-tomato-Timd4 plasmid was sequenced and confirmed to obtain a pZ-tomato-Timd4 plasmid with the correct sequence.
[0085] Table 5 Reaction system of Gibson ligation of promoter and homology arm
[0086]
[0087] Table 6 Reaction system of Gibson connection of Donor linear skeleton
[0088]
[0089] Step 5: Construction of pX459-Timd4 plasmid
[0090] (1) Determine the PAM site of the Timd4 gene promoter, construct a double-stranded gRNA fragment, the sequence is shown in SEQ ID No. 10 and SEQ ID No. 11 in Table 7, use pX459 plasmid as the vector, and after Bbs I digestion,
[0091] The double-stranded gRNA fragment was ligated to the pX459 vector to obtain the pX459-Timd4 plasmid.
[0092] (2) The pX459-Timd4 plasmid was transformed into competent E. coli cells, plated and cultured, screened, and PCR reaction was performed to verify the single clone. The identification primers are shown in Table 7 as SEQ ID No. 11, SEQ ID No. 12,
[0093] The PCR system and reaction conditions are shown in Table 8.
[0094] (3) The positive single clones were screened and cultured in a test tube containing 5 mL of LB+Amp liquid culture medium for 12 to 16 h (120 rpm, 37°C).
[0095] (4) Collect the bacteria, use a plasmid DNA large-scale extraction kit to extract the pX459-Timd4 plasmid from Escherichia coli, and perform sequencing to confirm that the pX459-Timd4 plasmid with the correct sequence is obtained.
[0096] Table 7 Primers for verification of pX459-Timd4 plasmid
[0097]
[0098] Table 8 pX459-Timd4 plasmid verification PCR reaction system and conditions
[0099]
[0100] Step 6: Cell transfection and positive screening
[0101] 10 μg of pX459-Timd4 plasmid and pZ-Tomato-Timd4 plasmid were mixed with 100 μL Opti-MEM solution and electroporated into 10*6 mammary epithelial cells. The electroporation conditions are shown in Table 9. The results are shown in Figure 5As shown, the expression of red fluorescence (tdTomato protein) can be detected in mammary epithelial cells, which preliminarily indicates that the overexpression plasmid has been successfully transferred into the cells. After 24 hours, flow sorting was performed, and when the cell confluence reached 60-70%, 1 μg / mL puromycin was used for resistance screening to obtain mammary epithelial cells that stably overexpressed the goat Timd4 gene. Subsequently, the collected mammary epithelial cells were cultured for monoclonal cloning, and after two weeks, the single cells grew into cell clusters.
[0102] Table 9 Electroporation conditions
[0103]
[0104] Step 7: Identification of Timd4 gene overexpression
[0105] When the single cells grew into cell clusters, they were digested and lysed, and RNA and protein were extracted for real-time fluorescence quantification and protein immunoblotting to detect Timd4 expression. The results were as follows: Figure 6 As shown, the results showed that compared with the wild-type mammary epithelial cells (NC), the RNA and protein of the Timd4 gene after transfection increased significantly, indicating that the gRNA successfully overexpressed the Timd4 gene, and a positive clone cell line was obtained and named GMEC-Timd4-OE-Cell line.
[0106] Step 8: LPS-induced mammary inflammation model
[0107] After the wild-type mammary epithelial cells and the gene-overexpressing mammary epithelial cell GMEC-Timd4-OE-Cell line were revived, when the cell confluence reached 70% to 80%, 10 μg / mL LPS was added for 12 hours, and the total cell mRNA was extracted using the Trizol method. The expression levels of inflammatory factor genes were detected by real-time fluorescence quantitative PCR. The results showed that in the LPS-induced mastitis model, overexpression of the Timd4 gene significantly reduced the expression of inflammatory factors (IL-6, IL-1B, TNF-a, NF-kB), indicating that in the process of mammary epithelial inflammation, overexpression of the Timd4 gene can significantly inhibit the expression of inflammatory factors, thereby alleviating the inflammatory state of the cells.
[0108] Table 10 Primers for Real-Time PCR detection of inflammatory factors
[0109]
[0110]
[0111] The contents not described in detail in this specification belong to the prior art known to professional and technical personnel in this field.
[0112] Finally, it should be noted that the above description is only a preferred example of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A method for constructing goat mammary epithelial cells overexpressing the Timd4 gene, characterized in that: Using gene editing technology, the promoter encoding the Timd4 gene was replaced with the promoter of the endogenous b-actin gene, which strongly expressed the Timd4 gene, and primary mammary epithelial cells that stably overexpressed the goat Timd4 gene were obtained. The specific steps include: S1. Amplification of the repair fragment b-actin promoter: Using goat genomic DNA as a template, the b-actin promoter was amplified by PCR and purified; the nucleotide sequence of the b-actin promoter is shown in SEQ ID No.1; S2. Amplification of the left and right homology arms of the Timd4 gene: Using the genomic DNA of goat Timd4 as a template, 1 kb before and after the 5'UTR of the Timd4 gene was used as the left and right homology arms for PCR amplification and purification; The nucleotide sequence of the left homologous arm of the Timd4 gene is shown in SEQ ID No.2; the nucleotide sequence of the right homologous arm of the Timd4 gene is shown in SEQ ID No.3; S3. Preparation of Donor linear backbone: pZ-Tomato plasmid was double-digested with Sal I endonuclease and Hind III endonuclease, purified, and Donor linear backbone was obtained; S4. Construction of pZ-Tomato-Timd4 plasmid: digest the b-actin promoter obtained in S1 and the left homology arm and right homology arm fragments of the Timd4 gene obtained in S2, and connect them to obtain homology arm fragments: left homology arm-promoter-right homology arm; connect the homology arm fragments with the Donor linear skeleton obtained in S3 to construct pZ-Tomato-Timd4 plasmid; S5. Construction of pX459-Timd4 plasmid: Determine the PAM site of the Timd4 gene promoter and construct a double-stranded gRNA fragment; after the pX459 vector is digested with Bbs I, the double-stranded gRNA fragment is connected to the pX459 plasmid vector to obtain the pX459-Timd4 plasmid; S6. The pX459-Timd4 plasmid obtained in S5 and the pZ-Tomato-Timd4 plasmid obtained in S4 were electroporated into goat mammary epithelial cells at a mass ratio of 1:1, and resistance screening was performed to obtain mammary epithelial cells that stably overexpressed the goat Timd4 gene.
2. The method for constructing goat mammary epithelial cells with overexpression of Timd4 gene according to claim 1, characterized in that: The sequence of the gRNA is shown in SEQ ID No.10 and SEQ ID No.
11.
3. The method for constructing goat mammary epithelial cells with overexpression of Timd4 gene according to claim 1, characterized in that: The sequences of the primers used for amplifying the repair fragment b-actin promoter in S1 are shown in SEQ ID No.4 and SEQ ID No.
5.
4. The method for constructing goat mammary epithelial cells with overexpression of Timd4 gene according to claim 1, characterized in that: The sequences of the primers used to amplify the left homologous arm of the Timd4 gene in S2 are shown in SEQ ID No.6 and SEQ ID No.7; the sequences of the primers used to amplify the right homologous arm of the Timd4 gene are shown in SEQ ID No.8 and SEQ ID No.
9.
5. The method for constructing goat mammary epithelial cells with overexpression of Timd4 gene according to claim 1, characterized in that: The verification primer sequences of the pX459-Timd4 plasmid in S5 are shown in SEQ ID No.11 and SEQ ID No.
12.
6. The method for constructing goat mammary epithelial cells with overexpression of Timd4 gene according to claim 1, characterized in that: The mass ratio of the left and right homology arms and the promoter in S4 is 1:1:2; the homology arm fragments and the Donor linear backbone are connected by Gibson, and the mass ratio of the homology arm fragments and the Donor linear backbone is 2:
1.
7. Goat mammary epithelial cells with overexpression of Timd4 gene constructed by the method according to any one of claims 1 to 6.
8. Use of the goat mammary epithelial cells overexpressing the Timd4 gene according to any one of claims 1 to 6 in constructing an inflammatory response animal model.
9. The use according to claim 8, characterized in that: The steps to construct an animal model of inflammatory response are: After wild-type goat mammary epithelial cells and gene-overexpressing mammary epithelial cells were revived, when the cell confluence reached 70% to 80%, 10 μg / mL LPS was added for treatment for 12 hours, total cell mRNA was extracted, and the expression levels of inflammatory factor genes were detected by real-time fluorescence quantitative PCR.
10. The use according to claim 9, characterized in that: The sequences of the primers for PCR detection of inflammatory factors are shown in SEQ ID No.13 to SEQ ID No.22.
